Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryOct182009	Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming Development of Two Week Method for Generating Human Induced Pluripotent Stem Cells with 200-Fold Increase in Yield Read All »	View HTML Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 11.2 KB
Toggle SummaryDec112017	Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 Stage All Subjects Achieved Day 100 Relapse-free Survival All Incidents of Day 100 Acute GvHD Responded to Steroid Treatment Randomized, Controlled and Double-Blinded Phase 2 Stage of PROTECT Now Enrolling SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 Stage 25.6 KB
Toggle SummaryNov042021	Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting FT596 Oral and FT516 Poster Presentations to Highlight Updated Clinical Data for Relapsed / Refractory Lymphoma on Monday, December 13 Company to Host Virtual Investor Event on Tuesday, December 14 SAN DIEGO , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML
Toggle SummaryFeb212011	Fate Therapeutics Announces Emerging Data From Proof-Of-Concept FT1050 Clinical Trial and Receives Orphan Drug Designation Encouraging Phase 1b Clinical Data Presented at 2011 BMT Tandem Meetings Read All »	View HTML Fate Therapeutics Announces Emerging Data From Proof-Of-Concept FT1050 Clinical Trial and Receives Orphan Drug Designation 12.6 KB
Toggle SummaryFeb212011	Fate Therapeutics Announces Encouraging Clinical Results and Change in Management Fate Therapeutics announces encouraging clinical results and change in management San Diego, CA – February 21, 2011 – In parallel with announcing encouraging clinical data at the 2011 BMT Tandem Meetings from its ongoing proof-of-concept FT1050 Phase 1b trial, Fate Therapeutics Read All »	View HTML Fate Therapeutics announces encouraging clinical results and change in management 12.6 KB
Toggle SummaryNov112018	Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500 NK100 Shows Clinical Benefit in Treating Advanced Hematologic Malignancies and Solid Tumors Disease Control Shown in All Subjects Re-treated with Second Dose of NK100 No NK100-related Dose Limiting Toxicities Reported Submitted Data to FDA Demonstrating FT500 Master iPSC Bank is Free of Read All »	View HTML
Toggle SummaryMay132021	Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia 4 of 9 Patients in FT516 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow 2 Patients in Second Dose Escalation Cohort of FT516 Monotherapy Study Continued in Remission without Further Therapeutic Intervention at 6-month Follow-up 1 of 3 Read All »	View HTML
Toggle SummaryJul142020	Fate Therapeutics Announces Exclusive License Agreement with Baylor College of Medicine for Rejection-resistant iPSC-derived Cellular Therapies License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients Preclinical Data Published in the Journal Nature Biotechnology Demonstrate Allogeneic CAR T Cells Overcome Immune Rejection and Exhibit Durable Tumor Read All »	View HTML
Toggle SummaryNov072022	Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors Multiplexed-engineered, iPSC-derived CAR T-cell Product Candidate Demonstrated Broad, Potent and Specific CAR Activity Across Multiple Preclinical Solid Tumor Models Fate and ONO to Jointly Develop and Commercialize FT825/ONO-8250 in U.S. and Europe with ONO having Exclusive Rights in Rest of World Read All »	View HTML
Toggle SummaryJan132020	Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood FT516 IND Application Cleared by FDA for Advanced Solid Tumors in Combination with PDL1-, EGFR- and HER2-targeting Therapeutic Antibodies Published Preclinical Data Demonstrate iPSC-derived NK Cells Engineered with High-affinity, Non-cleavable CD16 Enhance the Efficacy of Antibody Therapy SAN DIEGO Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.